Mylan is one of the world's leading global pharmaceutical companies. Our medicines include generic and brand name products in a variety of dosage forms, such as difficult-to-manufacture injectables, transdermal patches and HIV/AIDS antiretroviral (ARV) therapies. The company has innovative research and development capabilities and is one of the world's largest active pharmaceutical ingredient (API) manufacturers. Every one of our medications meets our one global quality standard regardless of where it is produced.

**Our Mission**

At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we:

- Innovate to satisfy unmet needs
- Make reliability and service excellence a habit
- Do what’s right, not what’s easy
- Impact the future through passionate global leadership

Creating better health for a better world. That’s what inspires Mylan in our mission to provide quality healthcare to the world’s 7 billion people, one person at time.

**Mylan Today**

Information reflects Mylan’s acquisition of Abbott's non-U.S. developed markets specialty and branded generics business.

- **Global workforce**: approximately 30,000
- **Products**: a global market portfolio of approximately 1,400 separate products
- **Product submissions**: more than 3,400 new product submissions pending regulatory approval around the world
- **Global presence**: sell products in approximately 145 countries and territories
- **U.S. presence**: one out of every 13 prescriptions dispensed in the U.S. – brand name or generic – is a Mylan product
- **Manufacturing presence**: operate 39 facilities in more than 10 countries
- **Manufacturing capacity**: a total capacity of 58 billion oral solid dosages, 3,600 kiloliters of API, 500 million injectable units, 260 million patches and 15 million semisolid units
- **R&D capabilities**: include an extensive range of dosage forms and delivery systems, including oral solid doses, transdermal patches, injectables, respiratory inhalants, topicals, soft gel capsules, nasal sprays, solutions, suspensions, ophthalmics, ARVs and APIs
- **ARV access**: approximately 40% of people living with HIV/AIDS in the developing world who are receiving treatment depend on a Mylan product
- **Notable**: member of S&P 500

**2014 Revenue**: $7.72 billion  
**Ticker**: NASDAQ: MYL
Our Evolution

1961  
Founded by Milan “Mike” Puskar and Don Panoz in White Sulphur Springs, West Virginia, U.S.

1973  
Became a publicly traded company

1984  
Received our first branded product approval

2002  
Generated more than $1 billion in revenue for the first time

2007  
Went global with the acquisitions of Matrix and Merck Generics

2012  
Championed the U.S. Food and Drug Administration Safety and Innovation Act

2013  
Acquired Agila Specialties and became a global injectables leader

2015  
Acquired Abbott's non-U.S. developed markets specialty and branded generics business

Key Access Initiatives

- Increase generic utilization
- Establish an effective generic biologics pathway
- Advance one global quality standard
- Enhance anaphylaxis awareness and expand access to epinephrine auto-injectors
- Stem the tide of HIV/AIDS

Executive Management Team

Robert J. Coury  
Executive Chairman

Rajiv Malik  
President

Heather Bresch  
Chief Executive Officer

John D. Sheehan  
Chief Financial Officer

Media Relations:  
+1.724.514.1968  
communications@mylan.com

Investor Relations:  
+1.724.514.1813  
investor.relations@mylan.com

Stay Connected  
Mylan.com  
LinkedIn  
YouTube  
@MylanNews  
@MylanCareers